Pontine Glioma - Pipeline Review, H1 2017

  • ID: 4311889
  • Report
  • 148 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Insys Therapeutics Inc
  • Midatech Pharma Plc
  • Ono Pharmaceutical Co Ltd
  • Sanofi
  • MORE
Pontine Glioma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Insys Therapeutics Inc
  • Midatech Pharma Plc
  • Ono Pharmaceutical Co Ltd
  • Sanofi
  • MORE
  1. Introduction
  2. Pontine Glioma - Overview
  3. Pontine Glioma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Pontine Glioma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Pontine Glioma - Companies Involved in Therapeutics Development
  15. AbbVie Inc
  16. Arog Pharmaceuticals Inc
  17. AstraZeneca Plc
  18. Boehringer Ingelheim GmbH
  19. Bristol-Myers Squibb Company
  20. Burzynski Research Institute Inc
  21. Insys Therapeutics Inc
  22. Loxo Oncology Inc
  23. Medicenna Therapeutics Corp
  24. Midatech Pharma Plc
  25. Novogen Ltd
  26. Ono Pharmaceutical Co Ltd
  27. Pfizer Inc
  28. Sanofi
  29. ZIOPHARM Oncology Inc
  30. Pontine Glioma - Drug Profiles
  31. (A-10 + AS-21) - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. AdRTSIL-12 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. afatinib dimaleate - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. AZD-1775 - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. cabazitaxel - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. cannabidiol - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. crenolanib besylate - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. depatuxizumab mafodotin - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. ipilimumab + nivolumab - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. larotrectinib - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. MDNA-55 - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. MTX-110 - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. MTX-111 - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. nivolumab - Drug Profile
  92. R&D Progress
  93. ORX-101 - Drug Profile
  94. Product Description
  95. Mechanism Of Action
  96. R&D Progress
  97. p28 - Drug Profile
  98. Product Description
  99. Mechanism Of Action
  100. R&D Progress
  101. pidilizumab - Drug Profile
  102. Product Description
  103. Mechanism Of Action
  104. R&D Progress
  105. Trilexium - Drug Profile
  106. Product Description
  107. Mechanism Of Action
  108. R&D Progress
  109. Vaccine for Pontine Glioma - Drug Profile
  110. Product Description
  111. Mechanism Of Action
  112. R&D Progress
  113. VIMO-001 - Drug Profile
  114. Product Description
  115. Mechanism Of Action
  116. R&D Progress
  117. Pontine Glioma - Dormant Projects
  118. Pontine Glioma - Product Development Milestones
  119. Featured News & Press Releases
  120. Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
  121. Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
  122. Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier
  123. May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
  124. Appendix
  125. Methodology
  126. Coverage
  127. Secondary Research
  128. Primary Research
  129. Expert Panel Validation
  130. Contact Us
  131. Disclaimer
List of Tables:
  1. Number of Products under Development for Pontine Glioma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Companies, H1 2017 (Contd..1), H1
  6. Products under Development by Universities/Institutes, H1
  7. Number of Products by Stage and Target, H1
  8. Number of Products by Stage and Mechanism of Action, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pontine Glioma - Pipeline by AbbVie Inc, H1
  12. Pontine Glioma - Pipeline by Arog Pharmaceuticals Inc, H1
  13. Pontine Glioma - Pipeline by AstraZeneca Plc, H1
  14. Pontine Glioma - Pipeline by Boehringer Ingelheim GmbH, H1
  15. Pontine Glioma - Pipeline by Bristol-Myers Squibb Company, H1
  16. Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H1
  17. Pontine Glioma - Pipeline by Insys Therapeutics Inc, H1
  18. Pontine Glioma - Pipeline by Loxo Oncology Inc, H1
  19. Pontine Glioma - Pipeline by Medicenna Therapeutics Corp, H1
  20. Pontine Glioma - Pipeline by Midatech Pharma Plc, H1
  21. Pontine Glioma - Pipeline by Novogen Ltd, H1
  22. Pontine Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1
  23. Pontine Glioma - Pipeline by Pfizer Inc, H1
  24. Pontine Glioma - Pipeline by Sanofi, H1
  25. Pontine Glioma - Pipeline by ZIOPHARM Oncology Inc, H1
  26. Pontine Glioma - Dormant Projects, H1
List of Figures:
  1. Number of Products under Development for Pontine Glioma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Top 10 Targets, H1
  4. Number of Products by Stage and Top 10 Targets, H1
  5. Number of Products by Top 10 Mechanism of Actions, H1
  6. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Arog Pharmaceuticals Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Burzynski Research Institute Inc
  • Insys Therapeutics Inc
  • Loxo Oncology Inc
  • Medicenna Therapeutics Corp
  • Midatech Pharma Plc
  • Novogen Ltd
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll